Novo Nordisk, the maker of Ozempic, reported that compounded versions of semaglutide, the main ingredient in Ozempic and ...

An Ozempic pen. Americans are increasingly calling poison control centers over semaglutide, the active ingredient in popular weight loss drugs Ozempic and Wegovy. Most of these calls appear to ...

Novo Nordisk scientist Lotte Knudsen, whose research led to Ozempic and Wegovy, started her career developing laundry ...

Ozempic (semaglutide) and Wegovy (semaglutide) are prescription drugs that may be used to help with long-term weight loss. But only Wegovy is FDA-approved for this use. Both drugs are approved for ...

Ever since their rise in popularity as weight loss drugs, there’s been a slew of reports on the potential adverse health ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

After years of ongoing shortages due to their growing popularity, all doses of both Ozempic and Wegovy are now listed as "available" on the U.S. Food and Drug Administration's drug shortage list.

After years in shortage, weight loss and diabetes drugs Ozempic and Wegovy are now considered to be “available” by the Food and Drug Administration. While the drugs remain on the agency’s ...

Novo Nordisk's Q3 2024 report highlights a 21% YoY sales increase with strong gains in GLP-1 diabetes and obesity drugs but ...

The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years of being considered in shortage by the Food and Drug Administration (FDA).